ABBOTT LABORATORIES (ABT) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-03-31..
Gross margin
Overview →Financial period ending 2026-03-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-03-31. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | Gross Profit |
| Revenue | 45.13B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 19.74B USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-03-31 | (m) | $45.13B | $19.74B | (m) |
| 2025-12-31 | (m) | $44.33B | $19.32B | (m) |
| 2025-09-30 | (m) | $43.84B | $19.34B | (m) |
| 2025-06-30 | (m) | $43.11B | $18.96B | (m) |
| 2025-03-31 | (m) | $42.34B | $18.71B | (m) |
| 2024-12-31 | (m) | $41.95B | $18.71B | (m) |
| 2024-09-30 | (m) | $41.22B | $18.32B | (m) |
| 2024-06-30 | (m) | $40.73B | $18.23B | (m) |
| 2024-03-31 | (m) | $40.33B | $18.11B | (m) |
| 2023-12-31 | (m) | $40.11B | $17.98B | (m) |
| 2023-09-30 | (m) | $39.96B | $18.01B | (m) |
| 2023-06-30 | (m) | $40.23B | $18.04B | (m) |
| 2023-03-31 | (m) | $41.51B | $18.49B | (m) |
| 2022-12-31 | (m) | $43.65B | $19.14B | (m) |
| 2022-09-30 | (m) | $45.03B | $19.32B | (m) |
| 2022-06-30 | (m) | $45.55B | $19.11B | (m) |
| 2022-03-31 | (m) | $44.51B | $19.12B | (m) |
| 2021-12-31 | (m) | $43.08B | $18.54B | (m) |
| 2021-09-30 | (m) | $42.31B | $18.26B | (m) |
| 2021-06-30 | (m) | $40.23B | $17.81B | (m) |
| 2021-03-31 | (m) | $37.34B | $16.12B | (m) |
| 2020-12-31 | (m) | $34.61B | $15.00B | (m) |
| 2020-09-30 | (m) | $32.22B | $13.94B | (m) |
| 2020-06-30 | (m) | $31.44B | $13.34B | (m) |
| 2020-03-31 | (m) | $32.09B | $13.35B | (m) |
| 2019-12-31 | $16.74B | $31.90B | $13.23B | 52.46% |
| 2019-09-30 | (m) | $31.36B | $12.99B | (m) |
| 2019-06-30 | (m) | $30.93B | $12.80B | (m) |
| 2019-03-31 | (m) | $30.72B | $12.80B | (m) |
| 2018-12-31 | $15.69B | $30.58B | $12.71B | 51.32% |
| 2018-09-30 | (m) | $30.40B | (m) | (m) |
| 2018-06-30 | (m) | $29.57B | (m) | (m) |
| 2018-03-31 | (m) | $28.45B | (m) | (m) |
| 2017-12-31 | $13.08B | $27.39B | (m) | 47.75% |
| 2017-09-30 | (m) | $25.13B | (m) | (m) |
| 2017-06-30 | (m) | $23.61B | (m) | (m) |
| 2017-03-31 | (m) | $22.30B | (m) | (m) |
| 2016-12-31 | $11.28B | $20.85B | (m) | 54.09% |
| 2016-09-30 | (m) | $20.71B | (m) | (m) |
| 2016-06-30 | (m) | $20.56B | (m) | (m) |
| 2016-03-31 | (m) | $20.39B | (m) | (m) |
| 2015-12-31 | $11.06B | $20.41B | (m) | 54.19% |
| 2015-09-30 | (m) | $20.57B | (m) | (m) |
| 2015-06-30 | (m) | $20.50B | (m) | (m) |
| 2015-03-31 | (m) | $20.39B | (m) | (m) |
| 2014-12-31 | $10.47B | $20.25B | (m) | 51.73% |
| 2014-09-30 | (m) | $22.16B | (m) | (m) |
| 2014-06-30 | (m) | $21.82B | (m) | (m) |
| 2014-03-31 | (m) | $21.71B | (m) | (m) |
| 2013-12-31 | $11.02B | $21.85B | (m) | 50.43% |
| 2013-09-30 | (m) | $40.21B | (m) | (m) |
| 2013-06-30 | (m) | $40.10B | (m) | (m) |
| 2013-03-31 | (m) | $39.97B | (m) | (m) |
| 2012-12-31 | $24.75B | $39.87B | (m) | 62.08% |
| 2012-09-30 | (m) | $39.41B | (m) | (m) |
| 2012-06-30 | (m) | $39.46B | (m) | (m) |
| 2012-03-31 | (m) | $39.27B | (m) | (m) |
| 2011-12-31 | $23.31B | $38.85B | (m) | 60.00% |
| 2011-09-30 | (m) | $38.44B | (m) | (m) |
| 2011-06-30 | (m) | $37.30B | (m) | (m) |
| 2011-03-31 | (m) | $36.51B | (m) | (m) |
| 2010-12-31 | $20.50B | $35.17B | (m) | 58.30% |
| 2010-09-30 | (m) | $33.99B | (m) | (m) |
| 2010-06-30 | (m) | $33.08B | (m) | (m) |
| 2010-03-31 | (m) | $31.74B | (m) | (m) |
| 2009-12-31 | (m) | $30.76B | (m) | (m) |
| 2009-09-30 | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) | (m) |
| 2009-03-31 | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | $29.53B | (m) | (m) |
| 2008-09-30 | (m) | (m) | (m) | (m) |
| 2008-06-30 | (m) | (m) | (m) | (m) |
| 2008-03-31 | (m) | (m) | (m) | (m) |
| 2007-12-31 | (m) | $25.91B | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |